Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Novel Drug Delivery Methods and Treatment Approaches for Retinal Diseases

Video Series

Novel intravitreal injections: Faricimab and aflibercept 8mg for the treatment of retinal diseases

Videos

A panelist discusses novel treatments for retinal vascular diseases, including faricimab, aflibercept, and port delivery system with ranibizumab.

Overview of Novel Treatments for Retinal Vascular Diseases

Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.

Overview and Benefits of Port Delivery System with Ranibizumab

Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their number of clinic visits while maintaining therapeutic effectiveness.

Patient Selection for Port Delivery System

Panelists discuss how successful implementation of the port delivery system requires careful attention to surgical technique during both initial implantation and subsequent refill procedures, with specialized training and protocols that differ significantly from standard intravitreal injections in terms of procedural steps, sterility requirements, and patient preparation.

Considerations for Surgical Implant of the Port Delivery System and Refill Process

Dr Jordan Graff highlights key steps in implanting the port delivery system, emphasizing incision and closure techniques with video clips.

Key Steps in the Surgical Implantation of the Port Delivery System

Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.

Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System

Panelists discuss how careful patient selection and management of potential complications - including surgical risks, device-related adverse events, and cost-benefit considerations requiring operating room resources - are crucial factors in successfully implementing the port delivery system in clinical practice.

Adverse Events of the Port Delivery System and Addressing Challenges With Adoption

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Our disease focused Insights discussion feature Key Opinion Leaders (KOLs) and industry experts on topics that range from diagnosis and treatment to the patient journey, genetic testing and beyond.

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

EP: 1.Overview of Novel Treatments for Retinal Vascular Diseases

EP: 2.Overview and Benefits of Port Delivery System with Ranibizumab

EP: 3.Patient Selection for Port Delivery System

EP: 4.Considerations for Surgical Implant of the Port Delivery System and Refill Process

EP: 5.Key Steps in the Surgical Implantation of the Port Delivery System

EP: 6.Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System

EP: 7.Adverse Events of the Port Delivery System and Addressing Challenges With Adoption

EP: 8.Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases